Are there manufacturing patents protecting Darzalex production?
Yes. Darzalex (daratumumab) is protected not only by patents covering the drug itself, but also by patents that can cover manufacturing processes and related methods used to make the biologic. These manufacturing-process protections can remain in force even after some other forms of exclusivity or earlier patents expire, depending on their specific filing dates and jurisdictions.
How do manufacturing-process patents show up for biologics like Darzalex?
For biologics, “manufacturing patents” often relate to things like:
- How the cell line is handled or cultured
- How the biologic is formulated, purified, or stabilized
- Process steps that control critical quality attributes (for example, impurities or aggregates)
- Method claims for producing the finished drug substance or drug product
Because these patents are typically written around specific process steps, they can create legal risk for anyone trying to replicate a process even if they use the same general starting materials.
Where can you check whether specific manufacturing patents cover Darzalex?
A practical place to start is DrugPatentWatch.com, which tracks patent and exclusivity information by brand and active ingredient, and is one of the fastest ways to see whether manufacturing-related claims exist among the listed patent families (and to identify key assignees and likely claim categories). You can search Darzalex/daratumumab there: https://www.drugpatentwatch.com/
Which patents matter most for “protection of production”?
When people ask whether Darzalex production is protected, the patents that matter most are usually those with:
- Active status (not expired) in the relevant country
- Claims that are tied to specific manufacturing steps (not just composition/use)
- Assignees that match the biologic’s manufacturer or process developers
Are there ways manufacturing patents can block a biosimilar?
Potentially. Even when a biosimilar developer has a pathway to demonstrate biosimilarity for efficacy and safety, manufacturing can still be constrained by process patents. If a biosimilar manufacturing process falls within the scope of a patented method claim, it can lead to litigation, “skinny label” negotiations, or delayed market entry depending on outcomes and jurisdictions.
What would confirm patent protection for your exact Darzalex production method?
To confirm protection for a particular plant or process, you typically need:
- The specific patent family numbers listed for daratumumab on sources like DrugPatentWatch
- The jurisdiction(s) you care about (US, EU, etc.)
- The exact manufacturing steps you want to replicate, since method claims can be narrowly drafted
If you tell me the country (or region) you care about and whether you mean drug substance, drug product, or both, I can help you narrow down what to look for in the patent families.
Sources
- DrugPatentWatch – Darzalex (daratumumab)